Chemotherapy-induced hepatotoxicity

Clinics in Liver Disease

Volumn 17, Issue 4, 2013, Pages 671-686

  Thatishetty, Ameet V ^a   Agresti, Nicholas ^a   O'Brien, Christopher B ^b  

^a Memorial Health   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Chemotherapy; Drugs; Hepatotoxicity; Liver

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; AZATHIOPRINE; BLEOMYCIN; BUSULFAN; CAPECITABINE; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; PHOSPHOTRANSFERASE INHIBITOR; PLATINUM DERIVATIVE; PROCARBAZINE; REVIMMUNE; STREPTOZOCIN; TAXANE DERIVATIVE; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC REACTION; BILIRUBIN BLOOD LEVEL; BLADDER CARCINOMA; BLADDER TUMOR; BONE MARROW TRANSPLANTATION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CHEMOTHERAPY INDUCED HEPATOTOXICITY; CHOLESTASIS; CHOLESTATIC HEPATITIS; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DAILY LIFE ACTIVITY; FATTY LIVER; FULMINANT HEPATIC FAILURE; GASTROINTESTINAL TUMOR; GENETIC VARIABILITY; HEAD AND NECK TUMOR; HEPATITIS; HEPATITIS B; HUMAN; IMMUNE RESPONSE; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; LIVER FUNCTION; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; LIVER VENOOCCLUSIVE DISEASE; LUNG CARCINOMA; LUNG TUMOR; MALIGNANT TRANSFORMATION; MELANOMA; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OVARY CANCER; PANCREAS CARCINOMA; PORTAL HYPERTENSION; RADIATION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STEM CELL TRANSPLANTATION; TOXIC HEPATITIS; VASCULITIS; VEIN OCCLUSION;

CANCER; CHEMOTHERAPY; DRUGS; HEPATOTOXICITY; LIVER;

ANTINEOPLASTIC AGENTS; DRUG-INDUCED LIVER INJURY; HUMANS;

EID: 84884981466     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.010     Document Type: Review

References (87)

1. Lewis J.H. Drug-induced liver disease. Med Clin North Am 2000, 84(5):1275-1311.
2. World Health Organization Common terminology criteria for adverse events v3.0 (CTCAE) 2006, World Health Organization, Available at:, Accessed March 11, 2013. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
3. National Cancer Institute Cancer therapy evaluation program 2005, National Cancer Institute, Available at:, Accessed March 11, 2013. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/newadverse_2006.pdf.
4. King P., Perry M.C. Hepatotoxicity of chemotherapy. Oncologist 2001, 6:162-176.
5. Hamilton M., Wolf J.L., Rusk J., et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006, 12:2166-2171.
6. Farrell G.C. Drug induced liver disease. JHepatol 2000, 32:77-88.
7. Zafrani E.S., Leclercq B., Vernant J.P., et al. Massive blastic infiltration of the liver: a cause of fulminant hepatic failure. Hepatology 1983, 3:428-432.
8. Ceci G., Bella M., Melissari M., et al. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer 1988, 61(10):1988-1991.
9. Le Counter D.G., Cogger V.C., Markus A.M., et al. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology 2001, 33:537-543.
10. Duvier A., Munro A., Verboy J. Treatment of psoriasis with azathioprine. Br Med J 1974, 1:49-51.
11. Twelves C., Glynne-Jones R. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999, 5(7):1696.
12. Wang W.S., Tzeng C.H., Chiou T.J., et al. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Jpn J Clin Oncol 1997, 27(3):154-157.
13. Pizzuto J., Avilés A. Cytosine arabinoside induced liver damage: histopathologic demonstration. Med Pediatr Oncol 1983, 11(4):287.
14. Bateman J.R., Pugh R.P., Cassidy F.R., et al. 5-Fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer 1971, 28:907-913.
15. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. JClin Oncol 2006, 24(31):4983.
16. Hubert C., Sempoux C., Horsmans Y., et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?. Liver Int 2007, 27(7):938.
17. Zalcberg J.R., Kemeny N.E. Systemic or regional chemotherapy for liver metastases from colorectal cancer: has the wheel stopped spinning?. Cancer J 2004, 10:271.
18. Doria M.I., Shepard K.V., Levin B., et al. Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR. Cancer 1986, 58:855-861.
19. Chang A.E., Schneider P.D., Sugarbaker P.H., et al. Aprospective randomized trial of regional versus systemic continuous 5-FudR chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987, 206:685-693.
20. Cerqueira P.A., Fernandes M.J. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry 2007, 13(30):8507-8515.
21. Aapro M.S., Martin C., Hatty S. Gemcitabine-a safety review. Anticancer Drugs 1998, 9(3):191.
22. Adamson P.C., Zimm S., Ragab A.H., et al. Aphase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol 1990, 26:343-344.
23. Present D.H., Meltzer S.J., Krumholtz M.P., et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989, 111:641-649.
24. Oancea I., Png C.W., Das I., et al. Anovel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity. Gut 2013, 62(4):594-605.
25. Podurgiel B.J., McGill D.B., Ludwig J., et al. Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc 1973, 48:787-792.
26. Palmer H.M. Hepatotoxicity of methotrexate in the treatment of psoriasis. Practitioner 1973, 263:324-328.
27. Karstens A., Kramer I. Chemical and physical stability of diluted busulfan infusion solutions. EJHP Science 2007, 13:40-47.
28. Morris L.E., Guthrie T.H. Busulfan induced hepatitis. Am J Gastroenterol 1988, 83:682-683.
29. Snyder L.S., Heigh R.L., Anderson M.L. Cyclophosphamide induced hepatotoxicity in a patient with Wegener's granulomatosis. Mayo Clin Proc 1993, 68:1203-1204.
30. Goldberg J.W., Lidsky M.D. Cyclophosphamide associated hepatotoxicity. South Med J 1985, 78:222-223.
31. Bacon A.M., Rosenberg S.A. Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. Ann Intern Med 1982, 97:62-66.
32. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. NEngl J Med 2000, 343(24):1750-1757.
33. Amromin G.D., Delman R.M., Shanbran E. Liver damage after chemotherapy for leukemia and lymphoma. Gastroenterology 1962, 42:401-410.
34. Bruhl P., Gunther U., Hoefer-Janker H., et al. Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumors. Int J Clin Pharmacol 1976, 14:29-39.
35. Facon T., Mary J.Y., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet 2007, 370(9594):1209-1218.
36. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001, 97(3):631.
37. Waksman S.A., Woodruff H.B. Bacteriostatic and bacteriocidal substances produced by soil actinomycetes. Proc Soc Exp Biol 1940, 45:609-614.
38. Ludwig R., Weirich A., Abel U., et al. Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH. Med Pediatr Oncol 1999, 33:462-469.
39. Blum R.H., Carter S.K., Agre K. Aclinical review of bleomycin. A new antineoplastic agent. Cancer 1973, 31:903-914.
40. Erichsen C., Jönsson P.E. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. JSurg Oncol 1984, 27(4):268.
41. McClay E., Lusch C.J., Mastrangelo M.J. Allergy-induced hepatic toxicity associated with dacarbazine. Cancer Treat Rep 1987, 71(2):219.
42. Frederick C.A., Williams L.D., Ughetto G., et al. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 1990, 29(10):2538-2549.
43. Avilés A., Herrera J., Ramos E., et al. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med 1984, 108(11):912.
44. Brenner D.E., Wiernik P.E., Wesley M., et al. Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute non-lymphocytic leukemia. Cancer 1984, 53:1042-1048.
45. Dorr R.T., Bowden G.T., Alberts D.S., et al. Interaction of mitomycin C with mammalian DNA detected by alkaline elution. Cancer Res 1985, 45:3510-3516.
46. Lazarus H.M., Gottfried M.R., Herzig R.H., et al. Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer 1982, 49(9):1789.
47. De Vita V.T., Carbone P.P., Owens A.H., et al. Clinical trials with 1,3-bis (2-chloroethyl)-nitrosourea, NSC-409962. Cancer Res 1965, 25:1876-1881.
48. Wolff S.N. High-dose carmustine and high-dose etoposide: a treatment regimen resulting in enhanced hepatic toxicity. Cancer Treat Rep 1986, 70:1464-1465.
49. Postma T.J., van Groeningen C.J., Witjes R.J., et al. Neurotoxicity of combination chemotherapy with procarbazine, CCNU [lomustine] and vincristine (PCV) for recurrent glioma. JNeurooncol 1998, 38(1):69-75.
50. Broder L.E., Carter S.K. Pancreatic islet cell carcinoma II: results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973, 79:108-118.
51. Hirth J., Watkins P.B., Strawderman M., et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000, 6(4):1255.
52. Witteveen P., Marchetti S., Mergui-Roelvink M., et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment. JClin Oncol 2010, 28:224s. [abstract # 2582].
53. Desai Z.R., Van den Berg H.W., Bridges J.M., et al. Can severe vincristine neurotoxicity be prevented?. Cancer Chemother Pharmacol 1982, 8(2):211.
54. Hohneker J.A. Asummary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994, 21(5 Suppl 10):42.
55. Saltz L.B., Douillard J.Y., Pirotta N., et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer, a new survival standard. Oncologist 2001, 6:81-91.
56. Felix F.G., Ritter J., Goodwin J.W., et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on respectability of hepatic colorectal metastases. JAm Coll Surg 2000, 205:845-853.
57. Creemers G.J., Lund B., Verweijt J. Topoisomersase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994, 20:73-96.
58. Tran A., Housset C., Boboc B., et al. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. JHepatol 1991, 12(1):36.
59. Hruban R.H., Sternberg S.S., Meyers P., et al. Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest 1991, 9(3):263.
60. Christian M.C. Two toxicities associated with carboplatin use: A. gross hematuria B. hepatic veno-occlusive disease 1989, Department of Health & Human Services bulletin, National Institutes of Health, National Cancer Institute, Bethesda (MD).
61. Cavalli F., Tschopp L., Sonntag R.W., et al. Acase of liver toxicity following cis-dichlorodiammineplatinum(II) treatment. Cancer Treat Rep 1978, 62(12):2125.
62. Pollera C.F., Ameglio F., Nardi M., et al. Cisplatin-induced hepatic toxicity. JClin Oncol 1987, 5(2):318.
63. Fakih M.G. 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment ofmetastatic colon cancer with severe liver dysfunction. Oncology 2004, 67(3-4):222.
64. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004, 15:460-466.
65. Miller A.A., Murry D.J., Owzar K., et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction. JClin Oncol 2007, 25(21):3055.
66. Liu W., Makrauer F.L., Qamar A.A., et al. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007, 5(8):91.
67. Iressa (gefitinib) [package insert]. Macclesfield (United Kingdom): AstraZeneca; 2004.
68. Gleevac (imantinib mesylate) [package insert]. East Hanover (NJ): Novartis Pharma; 2001.
69. Cross T.J., Bagot C., Portmann B., et al. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006, 81(3):189.
70. Xu C.F., Reck B.H., Xue Z., et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010, 102(9):1371.
71. Teo Y.L., Ho H.K., Chan A. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev 2013, 39(2):199-206.
72. George D.D., Peter R., Yoon-Koo K., et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381(9863):295-302.
73. Awada A., Hendlisz T., Gil T., et al. APhase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors. Br J Cancer 1992, 92:1855-1861.
74. Fairfax B., Pratap S., Roberts I., et al. Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. BMC Cancer 2012, 11:590.
75. Amarapurkar D.N. Prescribing medications in patients with decompensated liver cirrhosis. Int J Hepatol 2011, 2011:519526. 10.4061/2011/519526.
76. Avastin [package insert]. South San Francisco (CA): Genentech; 2004.
77. Susan D., Basak O., Honig A., et al. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treat Rev 2013, 39(6):622-631.
78. Quesada J., Hersh E.M., Manning J., et al. Treatment of hairy cell leukemia with recombinant alpha interferon. Blood 1985, 68:493-497.
79. Quesada J.R., Talpaz M., Rios A., et al. Clinical toxicity of interferons in cancer patients. JClin Oncol 1986, 4:234-243.
80. Nakagawa K., Miller F.N., Simds D.E., et al. Mechanisms of interleukin-2 induced hepatic toxicity. Cancer Res 1996, 56:507-510.
81. Fisher B., Keenan A.M., Garra B.S., et al. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. JClin Oncol 1989, 7:1852-1862.
82. Niu C., Yan H., Yu T., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315-3324.
83. Avramis V.I., Panosyan E.H. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 2005, 44(4):367-393.
84. Haskell C.M., Canellos G.P., Leventhal B.G., et al. Lasparaginase: therapeutic and toxic effects in patients with neoplastic disease. NEngl J Med 1969, 281:1028-1034.
85. Velcade (bortezomib) [package insert]. Cambridge (MA): Millennium Pharmaceuticals; 2003.
86. Heddle R., Calvert A.F. Hydroxyurea induced hepatitis. Med J Aust 1980, 1(3):121.
87. McMaster K.R., Hennigar G.R. Drug-induced granulomatous hepatitis. Lab Invest 1981, 44(1):61.